A short course of immunotherapy was found to be highly effective in a subset of patients with colon cancer. The treatment, which consisted of two cycles of immunotherapy prior to surgery, was effective in almost all patients. In two-thirds of patients,…
Treatment options for those suffering from endometriosis are currently few, but research at Umeå University provides new opportunities to understand the disease. A new thesis answers the question of how cells, which are normally found inside the uterus…
Phenotypic plasticity is a cancer hallmark, and lung adeno-to-squamous transition (AST) triggered by LKB1 inactivation is significantly associated with drug resistance. Clinical data show that squamous transition occurs in certain lung adenocarcinoma p…
Researchers have just taken the most fine-grained look to date at inflammatory pain: increased sensitivity to pain that follows an immune response to a wound, infection, sunburn, arthritis, or other trigger.
More than 16,000 Australians will be diagnosed with melanoma each year. Most of these will be caught early, and can be cured by surgery.
Bacteria, parasites, viruses—the immune system tackles them all. At the front line of the human immune response are cells called macrophages, which are responsible for correctly identifying intruders and then directing how the entire immune system resp…
In a phase 2 clinical trial, a new drug under development significantly reduced both the symptoms and disease process of a condition called Sjӧgren’s disease (SjD).
A new study reveals that aging human pancreatic beta cells display features of senescence while maintaining elevated levels of genes crucial for their function. Despite their aging status, these cells therefore exhibit an ability to release insulin in …
Immunotherapy is based on harnessing a person’s own immune system to attack cancer cells. However, patients with certain tumors do not respond to these therapies and it remains unclear why.
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.
